Current Knowledge About Immunotherapy Resistance for Melanoma and Potential Predictive and Prognostic Biomarkers

Overview

Journal Cancer Drug Resist

Date 2024 Jun 5

PMID 38835341

Authors

Lanni Song

Yixin Yang

Xuechen Tian

Affiliations

Soon will be listed here.

Abstract

Melanoma still reaches thousands of new diagnoses per year, and its aggressiveness makes recovery challenging, especially for those with stage III/IV unresectable melanoma. Immunotherapy, emerging as a beacon of hope, stands at the forefront of treatments for advanced melanoma. This review delves into the various immunotherapeutic strategies, prominently featuring cytokine immunotherapy, adoptive cell therapy, immune checkpoint inhibitors, and vaccinations. Among these, immune checkpoint inhibitors, notably anti-programmed cell death-1 (PD-1) and anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies, emerge as the leading strategy. However, a significant subset of melanoma patients remains unresponsive to these inhibitors, underscoring the need for potent biomarkers. Efficient biomarkers have the potential to revolutionize the therapeutic landscape by facilitating the design of personalized treatments for patients with melanoma. This comprehensive review highlights the latest advancements in melanoma immunotherapy and potential biomarkers at the epicenter of recent research endeavors.

References

Rosenberg S, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770):1318-21. DOI: 10.1126/science.3489291. View

Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi R . Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022; 21(1):20. PMC: 8764806. DOI: 10.1186/s12943-021-01490-9. View

Timar J, Ladanyi A . Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. Int J Mol Sci. 2022; 23(10). PMC: 9140388. DOI: 10.3390/ijms23105384. View

Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E . Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022; 40(3):318-334.e9. DOI: 10.1016/j.ccell.2022.01.002. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H . Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021; 39(24):2656-2666. PMC: 8376325. DOI: 10.1200/JCO.21.00612. View

Somasundaram R, Villanueva J, Herlyn M . Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol. 2012; 65:335-59. PMC: 3677516. DOI: 10.1016/B978-0-12-397927-8.00011-7. View

10.

Davar D, Wang H, Chauvin J, Pagliano O, Fourcade J, Ka M . Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018; :JCO1800632. PMC: 6286160. DOI: 10.1200/JCO.18.00632. View

11.

Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y . A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2020; 20(3):421-430. DOI: 10.1038/s41563-020-0793-6. View

12.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

13.

Zhao R, Chinai J, Buhl S, Scandiuzzi L, Ray A, Jeon H . HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A. 2013; 110(24):9879-84. PMC: 3683785. DOI: 10.1073/pnas.1303524110. View

14.

Blanchard L, Girard J . High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis. 2021; 24(4):719-753. PMC: 8487881. DOI: 10.1007/s10456-021-09792-8. View

15.

Zhu G, Shi Q, Zhao B, Liu Y, Feng T, Li C . Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study. J Cancer Res Clin Oncol. 2023; 149(9):6263-6269. DOI: 10.1007/s00432-023-04596-3. View

16.

Patel S, Othus M, Chen Y, Wright Jr G, Yost K, Hyngstrom J . Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023; 388(9):813-823. PMC: 10410527. DOI: 10.1056/NEJMoa2211437. View

17.

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi A . Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018; 6(1):74. PMC: 6048712. DOI: 10.1186/s40425-018-0383-1. View

18.

Montaner J, Ramiro L, Simats A, Tiedt S, Makris K, Jickling G . Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol. 2020; 16(5):247-264. DOI: 10.1038/s41582-020-0350-6. View

19.

Chan L, Nadkarni G, Fleming F, McCullough J, Connolly P, Mosoyan G . Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia. 2021; 64(7):1504-1515. PMC: 8187208. DOI: 10.1007/s00125-021-05444-0. View

20.

Adashek J, Kato S, Nishizaki D, Miyashita H, De P, Lee S . LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer Med. 2023; 12(12):13155-13166. PMC: 10315766. DOI: 10.1002/cam4.6000. View